| | | | | Product | Package Size | EFP | CP | SB | DC | Composition | Registr. Holder | Category | | | | |
---|
|
| | IP | CI | | Ebvallo | | PR | PR | k.A. | | | Pierre Fabre Pharma SA | A | FB | | G |  |
| | IP | CI | | Imodium ‐ I - T | 20 Kapsel(n) | 3.87 | 6.85 | 20 % | | Kapseln: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II (Switzerland) GmbH | D / SL / SO | FB | | G |  |
| | IP | CI | | Imodium - T | 60 Kapsel(n) | 9.40 | 26.60 | 20 % | | Kapseln: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II (Switzerland) GmbH | B / SL / SO | FB | | G |  |
L | | IP | CI | | Microlax | 4 x 5 ml | 4.15 | 7.65 | 10 % | | Klistier: 3 Active Agents | JNTL Consumer Health II (Switzerland) GmbH | D / SL | FB | | G |  |
L | | IP | CI | | Microlax | 12 x 5 ml | 12.45 | 23.00 | 10 % | | Klistier: 3 Active Agents | JNTL Consumer Health II (Switzerland) GmbH | D / SL / LPPV | FB | | G |  |
L | | IP | CI | | Microlax | 50 x 5 ml | 51.88 | 95.80 | 10 % | | Klistier: 3 Active Agents | JNTL Consumer Health II (Switzerland) GmbH | D / SL / LPPV | FB | | G |  |
L | | IP | | | Vegzelma 100 mg/4 ml | | 257.57 | 296.55 | 10 % | | Infusionskonzentrat: Bevacizumabum 100mg / 4ml | iQone Healthcare Switzerland SA | A / SL | FB | | G |  |
L | | IP | | | Vegzelma 400 mg/16 ml | | 962.84 | 1063.55 | 10 % | | Infusionskonzentrat: Bevacizumabum 400mg / 16ml | iQone Healthcare Switzerland SA | A / SL | FB | | G |  |
L | | IP | | PP | Herceptin subkutan 600mg/5ml | | 1484.04 | 1630.40 | 10 % | | Lösung zur subkutanen Injektion: Trastuzumabum 600mg / 5ml | Roche Pharma (Schweiz) AG | A / SL | FB | | G |  |
L | | IP | | | Ogivri 150 mg | | 456.84 | 513.25 | 10 % | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trastuzumabum 150 mg | Medius AG | A / SL | FB | | G |  |
| | IP | CI | | Bilaxten 6 mg / ml | 5 ml | PR | PR | k.A. | | Augentropfen: Bilastinum 6 mg/ml | A. Menarini GmbH | B | FB | | G |  |
| | IP | CI | | Imodium lingual akut | 10 | PR | PR | k.A. | | Schmelztabletten: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II (Switzerland) GmbH | D | FB | | G |  |
| | IP | CI | | Imodium lingual akut | 12 | PR | PR | k.A. | | Schmelztabletten: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II (Switzerland) GmbH | D | FB | | G |  |
| | IP | CI | | Nicorette Microtab Original-Aroma | 100 Tablette(n) | PR | PR | k.A. | | Sublingualtabletten: Nicotinum 2 mg | JNTL Consumer Health II (Switzerland) GmbH | D / LPPV | FB | | G |  |
| | IP | CI | | Regaine 5 % | 60 ml | PR | PR | k.A. | | Lösung: Minoxidilum 50 mg/ml | JNTL Consumer Health II (Switzerland) GmbH | D / LPPV | FB | | G |  |
| | IP | CI | | Regaine 5 % | 3 x 60 ml | PR | PR | k.A. | | Lösung: Minoxidilum 50 mg/ml | JNTL Consumer Health II (Switzerland) GmbH | D / LPPV | FB | | G |  |
| | IP | | | Mylotarg 5 mg | | PR | PR | k.A. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Gemtuzumabum Ozogamicinum 5 mg | Pfizer AG | A | FB | | G |  |
|
| | IP | CI | | Activelle | 28 Tablette(n) | 8.38 | 25.55 | 10 % | | Filmtabletten: 2 Active Agents | Novo Nordisk Pharma AG | B / SL | FB | | G |  |
| | IP | CI | | Kliogest N | 28 Tablette(n) | 8.20 | 25.35 | 10 % | | Filmtabletten: 2 Active Agents | Novo Nordisk Pharma AG | B / SL | FB | | G |  |
| | IP | CI | | Systen Conti | 8 Pflaster | 12.04 | 29.50 | 10 % | | patch transdermique: 2 Active Agents | Labatec Pharma SA | B / SL | FB | | G |  |
| | IP | CI | | Systen Conti | 24 Pflaster | 31.28 | 50.45 | 10 % | | patch transdermique: 2 Active Agents | Labatec Pharma SA | B / SL | FB | | G |  |
| | IP | CI | | Systen Sequi | 8 Pflaster | 7.66 | 17.55 | 10 % | | patch transdermique (emballage combiné): Estradiolum 3.1 mg patch transdermique (emballage combiné): 2 Active Agents | Labatec Pharma SA | B / SL | FB | | G |  |
| | IP | | | Estalis 50/140 | 8 Pflaster | 10.55 | 27.90 | k.A. | | Transdermales Pflaster: 2 Active Agents | Sandoz Pharmaceuticals AG | B | FB | | G |  |
| | IP | | | Estalis 50/140 | 24 Pflaster | 27.46 | 46.30 | k.A. | | Transdermales Pflaster: 2 Active Agents | Sandoz Pharmaceuticals AG | B | FB | | G |  |
| | IP | | | Estalis 50/250 | 8 Pflaster | 11.63 | 29.05 | k.A. | | Transdermales Pflaster: 2 Active Agents | Sandoz Pharmaceuticals AG | B | FB | | G |  |
| | IP | | | Estalis 50/250 | 24 Pflaster | 32.44 | 51.70 | k.A. | | Transdermales Pflaster: 2 Active Agents | Sandoz Pharmaceuticals AG | B | FB | | G |  |